Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook.

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S.

Global biopharmaceutical giant Takeda opens its first Asian Innovation Capability Centre in Bengaluru to speed-up drug discovery and development.

News: Takeda Innovation Capability Center to create over 750 jobs, significantly enhancing Bengaluru's global innovation ecosystem and digital expertise.

OSAKA, Japan & CAMBRIDGE, Mass., December 12, 2024--Takeda Spotlights High-Value, Late-Stage Pipeline of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas ...

Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept for ...

Pharmaceutical giant Takeda is closing its San Diego office at 9625 Towne Centre Drive. The local unit called Takeda Ventures focused on research and development.

Takeda has made some cuts to its clinical-phase pipeline, hacking off midphase programs and early-stage prospects as part of a push to focus on its most promising candidates. | Takeda has taken an ...

Takeda’s vision of becoming a leader in oncology ran into more trouble Thursday when the drugmaker axed (PDF) a midphase immunocytokine and three early-stage CAR-T cell therapy prospects from ...

Like in previous games, Ittetsu Takeda steps up as the head coach and once again motivates Shoyo through another inspirational speech regarding his well-being.

Takeda Pharmaceutical drug TAK-279 achieved the main goal of a mid-stage clinical trial in plaque psoriasis, setting the stage for Phase 3. The Japanese pharmaceutical giant sees the small ...